Table 1.

Src-altered resistance to targeted therapy in non-small-cell lung cancer (NSCLC).

Genomic Alternation of Src	Primary Mutation of NSCLC	Resistance to Target Therapy (Primary/Secondary)	Targeted Therapy Resistance	Type of Study	Reference
Overexpression of SHP2	EGFR mutation L858R/exon 19 deletion/G719X/L861Q	Primary	Erlotinib, Gefitinib, Afatinib	Clinical analysis	[39]
YES1 amplification	EGFR mutation L858R/exon 19 deletion	Secondary	Erlotinib, Afatinib	Clinical analysis	[37]
YES1 amplification	EGFR mutation Exon 19 deletion/L858R+T790M	Secondary	Osimertinib	Preclinical study	[38]
YES1 amplification	EGFR mutation L858R/exon 19 deletion ALK fusion EML4-ALK fusion/HIP1-ALK fusion	Secondary	Erlotinib, Afatinib, Crizotinib, Ceritinib	Clinical analysis	[40]

ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; EML4: echinoderm microtubule-associated protein-like 4.